Drug Trial Radar · NCT01499368
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
Last checked: Nov 19, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
495
Actual
Start
Nov 2011
Primary completion
Nov 2012
Study completion Nov 2012
Sponsor
- Lead sponsor
- Boryung Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 26, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the healing rate and safety of Lafutidine in erosive esophagitis
Conditions
- Erosive Esophagitis
Interventions
LafutidineDrug
Lafutidine 20mg/day
FamotidineDrug
Famotidine 40mg/day
OmeprazoleDrug
Omeprazole 20mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recovery Rates of Reflux EsophagitisTime frame: 8 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.